NVision Raises $55 Million Series B, Expands Into Quantum Computing for Drug Discovery
Updated
Updated · GlobeNewswire · May 13
NVision Raises $55 Million Series B, Expands Into Quantum Computing for Drug Discovery
1 articles · Updated · GlobeNewswire · May 13
$55 million in new funding will back NVision’s move beyond quantum sensing into quantum computing, with Abbott anchoring the Series B and the European Investment Bank providing a $17 million venture loan.
The expansion builds on NVision’s discovery of organic molecule-based qubits, which it is integrating onto photonic chips in a platform called PIQC to create a scalable quantum-computing approach for designing drug candidates.
NVision says that computing push complements its existing POLARIS system, which boosts MRI signals of sugar-based imaging agents to measure metabolism in real time and assess treatment response within hours to days.
POLARIS is already being installed at leading cancer centers, including Memorial Sloan Kettering, Cambridge and TU Munich, with about 20 sites across the U.S., Europe and Asia expected by year-end.
The round lifts NVision’s total capital raised to $120 million and underpins its broader strategy to pair quantum-based drug design with rapid in-vivo validation in healthcare.
Can one company truly master both quantum computing and medical imaging to revolutionize drug discovery?
Will quantum-enhanced MRI reveal disease secrets fast enough to justify a $120 million investment?
NVision Secures $55 Million Series B to Expand Quantum Healthcare Platform Globally
Overview
NVision, founded in 2015 in Ulm, Germany by a team of quantum experts, has leveraged the region’s strengths in quantum optics and microelectronics to pioneer parahydrogen-induced polarization (PHIP) technology. This innovation became the foundation for their POLARIS quantum-enhanced MRI platform. Early support from the German government and a successful Series A funding round enabled NVision to advance its technology and form key partnerships, such as with Siemens Healthineers. These strategic moves have positioned NVision at the forefront of integrating quantum sensing and computing to accelerate drug discovery and transform healthcare diagnostics.